rubschisandrin has been researched along with 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione in 1 studies
| Studies (rubschisandrin) | Trials (rubschisandrin) | Recent Studies (post-2010) (rubschisandrin) | Studies (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione) | Trials (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione) | Recent Studies (post-2010) (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione) |
|---|---|---|---|---|---|
| 5 | 0 | 2 | 126 | 1 | 84 |
| Protein | Taxonomy | rubschisandrin (IC50) | 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (IC50) |
|---|---|---|---|
| [tau protein] kinase | Oryctolagus cuniculus (rabbit) | 2 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 10 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 10 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 2.15 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 1.145 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 10 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 4.5 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 2.0608 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, G; Wang, J; Wang, Y; Wei, J; Yang, J; Zhang, J | 1 |
1 review(s) available for rubschisandrin and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
| Article | Year |
|---|---|
Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
Topics: Glycogen Synthase Kinase 3 beta; Humans; Neoplasms | 2022 |